151 related articles for article (PubMed ID: 7544569)
1. Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients.
Murphy G; Ragde H; Kenny G; Barren R; Erickson S; Tjoa B; Boynton A; Holmes E; Gilbaugh J; Douglas T
Anticancer Res; 1995; 15(4):1473-9. PubMed ID: 7544569
[TBL] [Abstract][Full Text] [Related]
2. Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen.
Murphy GP; Barren RJ; Erickson SJ; Bowes VA; Wolfert RL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Kenny GM; Ragde H; Boynton AL; Holmes EH
Cancer; 1996 Aug; 78(4):809-18. PubMed ID: 8756376
[TBL] [Abstract][Full Text] [Related]
3. Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients.
Murphy GP; Maguire RT; Rogers B; Partin AW; Nelp WB; Troychak MJ; Ragde H; Kenny GM; Barren RJ; Bowes VA; Gregorakis AK; Holmes EH; Boynton AL
Prostate; 1997 Dec; 33(4):281-5. PubMed ID: 9397201
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer.
Beckett ML; Cazares LH; Vlahou A; Schellhammer PF; Wright GL
Clin Cancer Res; 1999 Dec; 5(12):4034-40. PubMed ID: 10632336
[TBL] [Abstract][Full Text] [Related]
5. Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement.
Murphy GP; Holmes EH; Boynton AL; Kenny GM; Ostenson RC; Erickson SJ; Barren RJ
Prostate; 1995 Mar; 26(3):164-8. PubMed ID: 7534919
[TBL] [Abstract][Full Text] [Related]
6. Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen.
Cama C; Olsson CA; Raffo AJ; Perlman H; Buttyan R; O'Toole K; McMahon D; Benson MC; Katz AE
J Urol; 1995 May; 153(5):1373-8. PubMed ID: 7536252
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific membrane antigen: current and future utility.
Gregorakis AK; Holmes EH; Murphy GP
Semin Urol Oncol; 1998 Feb; 16(1):2-12. PubMed ID: 9508077
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.
Kurek R; Nunez G; Tselis N; Konrad L; Martin T; Roeddiger S; Aumüller G; Zamboglou N; Lin DW; Tunn UW; Renneberg H
Clin Cancer Res; 2004 Sep; 10(17):5808-14. PubMed ID: 15355910
[TBL] [Abstract][Full Text] [Related]
9. [Clinical significance of expression of PSA, hK2, PSMA in the peripheral blood of patients with prostate cancer].
Cui WG; Zhao H; Song YZ; Zhang J; Zhang LG; Shi JD; Qiang WM
Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):479-81. PubMed ID: 15555338
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer.
Murphy GP; Troychak MJ; Cobb OE; Bowes VA; Kenny RJ; Barren RJ; Kenny GM; Ragde H; Holmes EH; Wolfert RL
Prostate; 1997 Oct; 33(2):141-6. PubMed ID: 9316655
[TBL] [Abstract][Full Text] [Related]
11. Effect of exogenous testosterone replacement on prostate-specific antigen and prostate-specific membrane antigen levels in hypogonadal men.
Douglas TH; Connelly RR; McLeod DG; Erickson SJ; Barren R; Murphy GP
J Surg Oncol; 1995 Aug; 59(4):246-50. PubMed ID: 7543173
[TBL] [Abstract][Full Text] [Related]
12. Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells.
Zhang Y; Zippe CD; Van Lente F; Klein EA; Gupta MK
Clin Cancer Res; 1997 Jul; 3(7):1215-20. PubMed ID: 9815802
[TBL] [Abstract][Full Text] [Related]
13. Detection of prostate-specific antigen- or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: clinical implications.
Millon R; Jacqmin D; Muller D; Guillot J; Eber M; Abecassis J
Eur Urol; 1999 Oct; 36(4):278-85. PubMed ID: 10473985
[TBL] [Abstract][Full Text] [Related]
14. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer.
Murphy GP; Kenny GM; Ragde H; Wolfert RL; Boynton AL; Holmes EH; Misrock SL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Gilbaugh J
Urology; 1998 May; 51(5A Suppl):89-97. PubMed ID: 9610563
[TBL] [Abstract][Full Text] [Related]
15. PSMA/PSA ratio evaluated by immunohistochemistry may improve diagnosis of prostate cancer.
Jemaa AB; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Oueslati R
J Immunoassay Immunochem; 2014; 35(1):48-59. PubMed ID: 24063616
[TBL] [Abstract][Full Text] [Related]
16. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
17. PSA-PSMA profiles and their impact on sera PSA levels and angiogenic activity in hyperplasia and human prostate cancer.
Ben Jemaa A; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Oueslati R
Pathol Biol (Paris); 2014 Jun; 62(3):129-36. PubMed ID: 24745345
[TBL] [Abstract][Full Text] [Related]
18. Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels of <10 ng/mL.
Birtle AJ; Freeman A; Masters JR; Payne HA; Harland SJ;
BJU Int; 2005 Aug; 96(3):303-7. PubMed ID: 16042718
[TBL] [Abstract][Full Text] [Related]
19. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
Sanli Y; Kuyumcu S; Sanli O; Buyukkaya F; İribaş A; Alcin G; Darendeliler E; Ozluk Y; Yildiz SO; Turkmen C
Ann Nucl Med; 2017 Nov; 31(9):709-717. PubMed ID: 28900854
[TBL] [Abstract][Full Text] [Related]
20. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
